GSE100922

Expression data from whole blood in CD patients undergoing HSCT.

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

42 case / 0 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Treatment of severely refractory Crohn’s disease (CD) patients remains a clinical challenge. Recent studies show efficacy of autologous hematopoietic stem cell transplant (HSCT) in these severely compromised patients. HSCT is thought to eliminate auto-reactive cells; however the mechanisms are incompletely understood. We followed a group of patients (n=18) receiving autologous HSCT, with 50% of them achieving endoscopic drug-free remission. To elucidate the mechanism driving efficacy we compared the immunological changes induced by HSCT in responders and non-responders.

Overall design

Blood from CD patients undergoing HSCT was collected into PAXgene tubes and frozen at -20ºC (PAXgene Blood RNA Tube / PreAnalytiX (Qiagen, Spain)). Simple Endoscopic Score for Crohn's Disease (SES-CD) index was used at baseline and during follow-up to assess endoscopic activity. Magnetic Resonance Indeex of Activity (MaRIA) was used at baseline and during forllow up in those patients in whom lesions could not be assessed by ileocolonoscopy; mucosal healing was defined as a segmental index < 7 in all ileocolonic segments. Response was defined as mucosal healing at 52 weeks after-HSCT. Blood RNA isolation was performed with the PAXgene Blood RNA Kit using an automated protocol of QIAcube (Qiagen, Spain). Purity and integrity of the total RNA is assessed through 2100 Bioanalyzer (Agilent, Germany) and then quantified by NanoDrop spectrophotometer (NanoDrop Technologies, USA). A total of 42 samples belonging to 14 patients were analized.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
42 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. Differences in Peripheral and Tissue Immune Cell Populations Following Haematopoietic Stem Cell Transplantation in Crohn's Disease Patients. Journal of Crohn's & colitis, 2019
Available

Metadata Quality Components

Analysis Readiness

Not ready
55% DE readiness

Contrast completeness

10/25 pts

Only one side of the contrast is present; downstream DE needs both groups.

Minimum group size

0/20 pts

Minimum group size cannot be evaluated until a complete contrast exists.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

0/10 pts

Critical warnings must be resolved before downstream analysis.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • No complete case/control contrast is available.
  • Critical dataset warnings must be resolved.

Next Steps

  • Resolve critical warnings before downstream analysis.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Blocked

No complete case/control grouping exists yet.

Review the sample grouping table and assign both case and control groups.

Minimum sample count met

Blocked

At least one group has fewer than 2 samples.

Choose a larger dataset or merge only scientifically valid groups.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Analysis preparation checklist contains blocked items.

No complete case/control or treatment/control contrast is available.

At least one comparison group has fewer than two samples.

Critical dataset warnings are present.

Assay context may require expert handling before DESeq2-style analysis.

Study design is model-system or unclear and should be reviewed before analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Crohn's disease Disease context came from Normalization rules.
  • Likely case group Crohn's disease 42 samples
  • Likely control group No control group detected 0 samples

Intent Interpretation

  • Downgrade or exclusion reason Comparison: Unclear study design. Specimen: Biofluid. Comparison suitability: 0%. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Interpreted disease metadata: Crohn's disease.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 30521002.
  • Publication context: Differences in Peripheral and Tissue Immune Cell Populations Following Haematopoietic Stem Cell Transplantation in Crohn's Disease Patients.. Journal of Crohn's & colitis, 2019. PMID 30521002. DOI 10.1093/ecco-jcc/jjy203.

Cautions

  • Comparison: Unclear study design. Specimen: Biofluid. Comparison suitability: 0%.
  • Downgraded for tissue search because it is a biofluid cohort.
  • Downgraded for tissue search because study design or specimen source is unclear.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Missing or unclear metadata. Unclear study design downgraded for patient tissue tumor-vs-normal search intent.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Missing or unclear metadata. Comparison - Unclear study design. Specimen - Biofluid. Comparison suitability: 0%.
  • Missing or unclear metadata. Downgraded for tissue search because study design or specimen source is unclear.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

156 fields

Sample Group Preview

42 rows shown
Show Hide
Study totals: Case 42 | Control 0 | Unassigned 0 | Excluded 0 | Ambiguous 0 42 rows shown
Group Role Accession Title Source / characteristics Reason
Crohn's disease Case GSM2696434 Blood-E09-T0_1 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 18; Disease location: Ileocolonic+L4; Disease phenotype: Inflammatory; Timepoint: W0; Response: Yes; Cdai: 230; Ses-cd: 18; Gender: Female Case marker detected.
Crohn's disease Case GSM2696435 Blood-D07-T52_2 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 18; Disease location: Ileocolonic+L4; Disease phenotype: Inflammatory; Timepoint: W52; Response: Yes; Cdai: 32.84; Ses-cd: 0; Gender: Female Case marker detected.
Crohn's disease Case GSM2696436 Blood-E05-T0_2 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 26; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W0; Response: No; Cdai: 419; Ses-cd: 36; Gender: Male Case marker detected.
Crohn's disease Case GSM2696437 Blood-D09-T13_2 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 26; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W13; Response: No; Cdai: 47.68; Ses-cd: NA; Gender: Male Case marker detected.
Crohn's disease Case GSM2696438 Blood-H05-T26_1 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 26; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W26; Response: No; Cdai: 72.76; Ses-cd: NA; Gender: Male Case marker detected.
Crohn's disease Case GSM2696439 Blood-A09-T52_3 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 27; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W52; Response: No; Cdai: 174.45; Ses-cd: 24; Gender: Male Case marker detected.
Crohn's disease Case GSM2696440 Blood-H09-T0_3 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 35; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W0; Response: Yes; Cdai: 332; Ses-cd: 26; Gender: Female Case marker detected.
Crohn's disease Case GSM2696441 Blood-F09-T13_1 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 35; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W13; Response: Yes; Cdai: 100.6; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696442 Blood-A07-T52_2 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 36; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W52; Response: Yes; Cdai: 88.22; Ses-cd: 2; Gender: Female Case marker detected.
Crohn's disease Case GSM2696443 Blood-A07-T0_1 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 26; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W0; Response: Yes; Cdai: 262.1; Ses-cd: 34; Gender: Male Case marker detected.
Crohn's disease Case GSM2696444 Blood-B07-T13_2 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 27; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W13; Response: Yes; Cdai: 47.72; Ses-cd: NA; Gender: Male Case marker detected.
Crohn's disease Case GSM2696445 Blood-A07-T26_3 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 27; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W26; Response: Yes; Cdai: 61.5; Ses-cd: 4; Gender: Male Case marker detected.
Crohn's disease Case GSM2696446 Blood-D05-T52_2 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 27; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W52; Response: Yes; Cdai: 24.74; Ses-cd: 4; Gender: Male Case marker detected.
Crohn's disease Case GSM2696447 Blood-E07-T0_1 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 33; Disease location: Ileocolonic+L4; Disease phenotype: Inflammatory; Timepoint: W0; Response: Yes; Cdai: 236; Ses-cd: 19; Gender: Female Case marker detected.
Crohn's disease Case GSM2696448 Blood-A05-T13_3 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 34; Disease location: Ileocolonic+L4; Disease phenotype: Inflammatory; Timepoint: W13; Response: Yes; Cdai: 156.6; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696449 Blood-F05-T26_3 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 34; Disease location: Ileocolonic+L4; Disease phenotype: Inflammatory; Timepoint: W26; Response: Yes; Cdai: 180.29; Ses-cd: 6; Gender: Female Case marker detected.
Crohn's disease Case GSM2696450 Blood-D07-T52_1 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 35; Disease location: Ileocolonic+L4; Disease phenotype: Inflammatory; Timepoint: W52; Response: Yes; Cdai: 54; Ses-cd: 4; Gender: Female Case marker detected.
Crohn's disease Case GSM2696451 Blood-B09-T0_2 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 33; Disease location: Ileocolonic; Disease phenotype: Fistulating; Timepoint: W0; Response: No; Cdai: 267.7; Ses-cd: 16; Gender: Male Case marker detected.
Crohn's disease Case GSM2696452 Blood-E05-T13_3 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 33; Disease location: Ileocolonic; Disease phenotype: Fistulating; Timepoint: W13; Response: No; Cdai: 215; Ses-cd: NA; Gender: Male Case marker detected.
Crohn's disease Case GSM2696453 Blood-E09-T26_3 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 34; Disease location: Ileocolonic; Disease phenotype: Fistulating; Timepoint: W26; Response: No; Cdai: 232; Ses-cd: 9; Gender: Male Case marker detected.
Crohn's disease Case GSM2696454 Blood-F09-T52_2 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 34; Disease location: Ileocolonic; Disease phenotype: Fistulating; Timepoint: W52; Response: No; Cdai: 264.8; Ses-cd: 16; Gender: Male Case marker detected.
Crohn's disease Case GSM2696455 Blood-D05-T0_1 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 32; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W0; Response: No; Cdai: 450; Ses-cd: 22; Gender: Female Case marker detected.
Crohn's disease Case GSM2696456 Blood-B09-T13_3 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 33; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W13; Response: No; Cdai: 333; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696457 Blood-H07-T26_3 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 34; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W26; Response: No; Cdai: 390; Ses-cd: 21; Gender: Female Case marker detected.
Crohn's disease Case GSM2696458 Blood-C07-T52_1 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 34; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W52; Response: No; Cdai: 382; Ses-cd: 21; Gender: Female Case marker detected.
Crohn's disease Case GSM2696459 Blood-C05-T0_3 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 24; Disease location: Ileal+L4; Disease phenotype: Stenosing; Timepoint: W0; Response: Yes; Cdai: 162.89; Ses-cd: 8; Gender: Female Case marker detected.
Crohn's disease Case GSM2696460 Blood-G07-T13_1 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 24; Disease location: Ileal+L4; Disease phenotype: Stenosing; Timepoint: W13; Response: Yes; Cdai: 107; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696461 Blood-E09-T26_2 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 24; Disease location: Ileal+L4; Disease phenotype: Stenosing; Timepoint: W26; Response: Yes; Cdai: 94; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696462 Blood-H05-T0_2 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 21; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W0; Response: Yes; Cdai: 278.66; Ses-cd: 20; Gender: Female Case marker detected.
Crohn's disease Case GSM2696463 Blood-C07-T13_3 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 21; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W13; Response: Yes; Cdai: 85; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696464 Blood-G09-T26_2 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 21; Disease location: Ileocolonic; Disease phenotype: Inflammatory; Timepoint: W26; Response: Yes; Cdai: 70.76; Ses-cd: 4; Gender: Female Case marker detected.
Crohn's disease Case GSM2696465 Blood-G05-T0_1 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 35; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W0; Response: Yes; Cdai: 336.64; Ses-cd: 19; Gender: Female Case marker detected.
Crohn's disease Case GSM2696466 Blood-F07-T26_3 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 36; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W26; Response: Yes; Cdai: 101; Ses-cd: 6; Gender: Female Case marker detected.
Crohn's disease Case GSM2696467 Blood-G07-T52_3 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 37; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W52; Response: Yes; Cdai: 1.5; Ses-cd: 6; Gender: Female Case marker detected.
Crohn's disease Case GSM2696468 Blood-F07-T0_1 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 24; Disease location: Ileocolonic+L4; Disease phenotype: Fistulating; Timepoint: W0; Response: Yes; Cdai: 149.37; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696469 Blood-H05-T13_3 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 25; Disease location: Ileocolonic+L4; Disease phenotype: Fistulating; Timepoint: W13; Response: Yes; Cdai: 128.72; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696470 Blood-D09-T26_3 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 25; Disease location: Ileocolonic+L4; Disease phenotype: Fistulating; Timepoint: W26; Response: Yes; Cdai: 40.9; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696471 Blood-G09-T52_3 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 26; Disease location: Ileocolonic+L4; Disease phenotype: Fistulating; Timepoint: W52; Response: Yes; Cdai: 153.1; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696472 Blood-A09-T0_2 Peripheral blood of Crohn's Disease patient collected at baseline Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 29; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W0; Response: Yes; Cdai: 335; Ses-cd: 12; Gender: Female Case marker detected.
Crohn's disease Case GSM2696473 Blood-F09-T13_3 Peripheral blood of Crohn's Disease patient collected at 13 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 29; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W13; Response: Yes; Cdai: 14; Ses-cd: NA; Gender: Female Case marker detected.
Crohn's disease Case GSM2696474 Blood-G05-T26_2 Peripheral blood of Crohn's Disease patient collected at 26 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 29; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W26; Response: Yes; Cdai: 14; Ses-cd: 0; Gender: Female Case marker detected.
Crohn's disease Case GSM2696475 Blood-B05-T52_2 Peripheral blood of Crohn's Disease patient collected at 52 weeks after HSCT Tissue: Peripheral blood; Diagnosis: Crohn’s disease (CD); Age: 30; Disease location: Colonic; Disease phenotype: Inflammatory; Timepoint: W52; Response: Yes; Cdai: 10; Ses-cd: 2; Gender: Female Case marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.